Anesthesia with ciprofol in cardiac surgery with cardiopulmonary bypass: A case report

• DOI: 10.12998/wjcc.v11.i1.157
• Publication Date: 2023-01-03T08:56:43Z
• Authors: Le Yu; Evelyne Bischof; Hui-Hong Lu
• Keywords: Bispectral index; Cardiac index

Ciprofol is a novel agent for intravenous general anesthesia. In February 2022, it was approved by the National Medical Products Administration anesthesia induction and maintenance. It has advantages of fast onset, elimination, stable circulation, few adverse reactions. However, efficacy safety ciprofol in cardiac surgery with cardiopulmonary bypass have not been reported. Here we describe case where successfully used bypass.A 72-year-old man (height 176 cm; weight 70 kg) diagnosed coronary atherosclerotic cardiomyopathy requiring artery grafting left ventricular aneurysmectomy. administered (0.4 mg/kg) maintenance (0.6-1.0 mg/kg/h) During entire operation, bispectral index, hemodynamics, blood oxygen saturation were maintained at normal levels. The patient recovered well after surgery, no serious events related to ciprofol.Ciprofol safe effective bypass.